About BioBDx
BioBDx is a Healthcare company based in Westford (United States) founded in 2004, and was acquired by Pearson in August 2013. Tools for ADHD symptom assessment via motion tracking are developed. BioBDx has raised $30.41 million across 11 funding rounds from investors including Pearson, Sevin Rosen and Tullis Health Investors. The company was acqui-hired. Its focus areas include Life Sciences, Neurology, In-Vitro Diagnostics and Psychiatric. Its legal entity is BioBehavioral Diagnostics Co. Its competitors include Assurex Health, Genomind and Premier Biotech; 2 of its 3 listed competitors have raised funding.
Company details
BioBehavioral Diagnostics (BioBDx) develops tools for the assessment of Attention deficit hyperactivity disorder (ADHD) symptoms. Its flagship product is the Quotient ADHD System, a tool that assesses ADHD symptoms by using advanced motion tracking technology to measure three core symptoms in the patient: hyperactivity, inattention and implusivity, while they complete a standardized test. It then uses proprietary algorithms to analyze and score patterns of motion, accuracy of the responses, and fluctuations in attention state. Quotient ADHD is currently approved by the US FDA. BioBDx was acquired by Pearson in August 2013.
- Headquarters Westford, United States
- Stage Acquired
- SectorsHealthcare
- Website biobdx.com
- Social LinkedIn X
- Acquired by Pearson (Aug 2013)
- Legal Name Biobehavioral Diagnostics Co
Funding Insights of BioBDx
BioBDx has successfully raised a total of $30.41M across 11 strategic funding rounds. The most recent funding activity was a Series C round of $500 thousand completed in February 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $30.41M
- Total Rounds 11
- Last Round Series C — $500,000
- First Round $8.5M
(Feb 2007)
- Investors Count 2
Latest 10 of 11 funding rounds of BioBDx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2013 | $500,000 | Series C | – | – | – |
| Oct 2012 | $2.45M | Series C | – | – | – |
| Jun 2012 | $5.16M | Series C | – | – | – |
| Sep 2011 | $3.08M | Debt – Conventional | – | – | – |
| May 2011 | $500,000 | Series B | – | – | – |
| Apr 2011 | $300,000 | Series B | – | – | – |
| Feb 2010 | $10M | Series B | – | Sevin Rosen, Tullis Health Investors | – |
| Jan 2010 | $500,000 | Debt – Conventional | – | – | – |
| Dec 2009 | $500,000 | Series B | – | – | – |
| Jun 2009 | $2.5M | Series B | – | – | – |
3 investors in total: 3 institutional.
Investors in BioBDx
BioBDx has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Pearson, Sevin Rosen and Tullis Health Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage US investments in technology and offline sectors are targeted. | srfunds.com | Dallas, United States | ||
Healthcare investments are made by Tullis Health Investors. | tullisfunds.com | Palm Beach Gardens, United States | ||
Provider of evidence-based learning products and solutions for learners and educators | 1836 | pearson.com | London, United Kingdom |
Investor details for BioBDx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of BioBDx
4 dated milestones of BioBDx across 9 years, from founding to its latest funding, stage changes and deals.
- Founded BioBDx is founded.
- Funding First funding round of $8.5M.
- Funding Latest funding round, Series C, of $500K.
- Exit Acquired by Pearson.
Competitors of BioBDx
BioBDx has 3 listed competitors in our database, 2 of them funded. They include Assurex Health, Genomind and Premier Biotech.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| assurexhealth.com | 2006 | Mason, United States | $84.47M | 390 | Personalized medication for neuropsychiatric conditions is guided by pharmacogenomics. | |
| genomind.com | 2009 | King Of Prussia, United States | $64.43M | Genetic tests for personalized mental health treatments are developed. | ||
| premierbiotech.com | 2009 | Minneapolis, United States | 102 | Rapid drug testing solutions and lab services are provided. |
Detailed competitors of BioBDx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as BioBDx (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biobdx
Complete news archive for BioBDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioBDx
BioBDx was founded in 2004 and raised its 1st funding round 3 years after it was founded.
BioBDx is headquartered in Westford, United States. It is registered at Westford, Massachusetts, United States.
BioBDx is a funded company, having raised a total of $30.41M across 11 funding rounds to date. The company's 1st funding round was a Series B of $2.5M, raised on Feb 2007.
BioBehavioral Diagnostics (BioBDx) develops tools for the assessment of Attention deficit hyperactivity disorder (ADHD) symptoms. Its flagship product is the Quotient ADHD System, a tool that assesses ADHD symptoms by using advanced motion tracking technology to measure three core symptoms in the patient: hyperactivity, inattention and implusivity, while they complete a standardized test. It then uses proprietary algorithms to analyze and score patterns of motion, accuracy of the responses, and fluctuations in attention state. Quotient ADHD is currently approved by the US FDA. BioBDx was acquired by Pearson in August 2013.
BioBDx's top competitors include Assurex Health, Genomind and Premier Biotech.
BioBDx has 3 investors. Key investors include Pearson, Sevin Rosen, and Tullis Health Investors.
BioBDx operates through Biobehavioral Diagnostics Co.
Yes. BioBDx was acquired by Pearson in August 2013.